22 June 2018 - HAS has posted the agenda for the next scheduled TC meeting.

The Transparency Commission will (re)consider the reimbursement of:

• Fluciclovine (F 18) (Axumin)
  
• Telotristat etiprate (Xermelo)
  
• Tolvaptan (Samsca)
  
• Emicizumab (Hemlibra)
  

Read TC agenda [French]